Victoria Socha

DocwireNews

Patients with end-stage renal disease who are receiving maintenance dialysis commonly develop anemia. A new class of small-molecule oral drugs for the treatment of anemia in chronic kidney disease, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) has emerged recently. The new agents demonstrate advantages of traditional exogeneous erythropoietin (EPO).Meiyan Wu, MD, and colleagues conducted a meta-analysis of studies comparing the safety and efficacy of HIF-PHI in erythropoiesis and iron metabolism with EPO in patients receiving maintenance dialysis. Results were reported in Clinical and Experimental Nephrology [doi.org/10.007/s10157-022-02263-4].The researchers utilized a sensitive search strategy to search PubMed, EMBASE, and Cochrane databases to identify all citations for randomized controlled trials comparing HIF-PHI agents with EPO/placebo through December 2021.A total of 14 randomized controlled trials including 2738 patients were identified. Using the random-effects model, there was no statistically significant difference found in hemoglobin increase (P=.37) between HIF-PHI treatment and EPO treatment. Administration of HIF-PHI upregulated transferrin (mean deviation [MD], 36.12; 95% CI, 27.04-45.20) and soluble transferrin receptors (MD, 1.28; 95% CI, 0.44-2.13), but did not statistically reduce hepcidin level (P=.37).Total and low density lipoprotein cholesterol levels were suppressed by HIF-PHI (MD, &ndash;0.99; 95% CI, &ndash;1.34 to &ndash;0.63 and MD, &ndash;0.99; 95% CI, &ndash;1.34 to &ndash;0.64, respectively). There was no difference in triglyceride between HIF-PHI and EPO treatment (P=.74).There were no differences in treatment-emergent adverse events between treatment with HIF-PHI and treatment with erythropoietin. In the fixed-effect model, treatment-emergent serious adverse events were higher in the HIF-PHI group than in those in the EPO controls.&ldquo;HIF-PHI could effectively upregulate and maintain hemoglobin levels in patients with anemia receiving maintenance dialysis. Furthermore, HIF-PHI could elevate iron metabolism activity and utility without inducing treatment-associated serious adverse events. Robust data from larger randomized controlled trials with longer treatment duration and follow-up are needed,&rdquo; the researchers said.

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

HIF-PHIs for Anemia in Patients Receiving Dialysis

Anemia and Kidney Disease

Patients with end-stage renal disease who are receiving maintenance dialysis commonly develop anemia. A new class of small-molecule oral drugs for the treatment of anemia in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe